Impact of home warfarin use on treatment patterns and bleeding complications for patients with non-ST-segment elevation acute coronary syndromes: Observations from the CRUSADE quality improvement initiative

European Heart Journal

Volumn 29, Issue 9, 2008, Pages 1103-1109

  Wang, Tracy Y ^a   Chen, Anita Y ^a   Peterson, Eric D ^a   Becker, Richard C ^a   Gibler, W Brian ^b   Ohman, E Magnus ^a   Roe, Matthew T ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Anticoagulation; Bleeding; NSTE ACS; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; WARFARIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOCARDIOGRAPHY; ANTICOAGULATION; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGE DISTRIBUTION; AGED; ANTICOAGULANTS; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME; WARFARIN;

EID: 45349084183     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehn126     Document Type: Article

References (17)

1. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002;287:337-344.
2. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE III, Steward DE, Theroux P, Gibbons RJ, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Smith SC Jr American College of Cardiology; American Heart Association. Committee on the Management of Patients With Unstable Angina. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002;40:1366-1374.
3. Fox KA, Steg PG, Eagle KA, Goodman SG, Anderson FA Jr, Granger CB, Flather MD, Budaj A, Quill A, Gore JM GRACE Investigators. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA 2007;297:1892-1900.
4. Moscucci M, Fox KA, Cannon CP, Klein W, López-Sendón J, Montalescot G, White K, Goldberg RJ. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003;24:1815-1823.
5. CRUSADE National Quality Initiative Available at: www.crusadeqi.com (accessed 20 November 2007).
6. Enoxaparin [package insert] Bridgewater NAPI.
7. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42:121-130.
8. Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL, Akkerhuis KM, Harrington RA, Deckers JW, Armstrong PW, Lincoff AM, Califf RM, Topol EJ, Simoons ML. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation 2000;101:2557-2567.
9. Malik AK, Taylor AJ. Can warfarin randomized trials be reproduced in 'real life'? Adherence to warfarin guidelines for intensity of anticoagulation in a university-based warfarin clinic. South Med J 2000;93:58-61.
10. Newman DH, Zhitomirsky I. The prevalence of nontherapeutic and dangerous international normalized ratios among patients receiving warfarin in the emergency department. Ann Emerg Med 2006;48:182-189. 189 e1.
11. Lidell C, Svedberg LE, Lindell P, Bandh S, Job B, Wallentin L. Clopidogrel and warfarin: absence of interaction in patients receiving long-term anticoagulant therapy for non-valvular atrial fibrillation. Thromb Haemost 2003;89:842-846.
12. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853-863.
13. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006;354:1464-1476.
14. Ansell J, Hirsh J, Dalen J, Bussey H, Anderson D, Poller L, Jacobson A, Deykin D, Matchar D. Managing oral anticoagulant therapy. Chest 2001;119(Suppl. 1):22S-38S.
15. Cura FA, Kapadia SR, L'Allier PL, Schneider JP, Kreindel MS, Silver MJ, Yadav JS, Simpfendorfer CC, Raymond RR, Tuzcu EM, Franco I, Whitlow PL, Topol EJ, Ellis SG. Safety of femoral closure devices after percutaneous coronary interventions in the era of glycoprotein IIb/IIIa platelet blockade. Am J Cardiol 2000;86:780-782. A9.
16. Jessup DB, Coletti AT, Muhlestein JB, Barry WH, Shean FC, Whisenant BK. Elective coronary angiography and percutaneous coronary intervention during uninterrupted warfarin therapy. Catheter Cardiovasc Interv 2003;60:180-184.
17. Chang RJ, Doherty TM, Goldberg SL. How does warfarin affect the activated coagulation time? Am Heart J 1998;136:477-479.